Urinary analgesics
This article was originally published in The Tan Sheet
Executive Summary
The availability of OTC urinary tract infection diagnostic kits in conjunction with the condition's "readily recognizable symptoms" combines to create a safe atmosphere for self-medication using phenazopyridine hydrochloride, Polymedica Pharmaceuticals maintains in recent comments filed with FDA. Current labeling requirements "are sufficient to ensure safe and effective" OTC consumer use of the ingredient, the Azo Standard marketer says. OTC urinary analgesic products "clearly instruct the consumer to seek appropriate medical attention if symptoms persist beyond a specific time," the firm adds, echoing separate comments filed by CHPA (1"The Tan Sheet" July 12, 2004, p. 6)...
You may also be interested in...
Urinary Analgesics’ Safe History Justifies Monograph Inclusion – CHPA
Urinary analgesic products' safe history of use in an over-the-counter setting support the establishment of an OTC monograph, the Consumer Health Products Association maintains in June 28 comments to FDA
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.